artenimol has been researched along with sirolimus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, G; Liu, N; Sheng, C; Wang, Y; Wu, S | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Li, Z; Liu, J; Teng, M; Wang, Y | 1 |
2 review(s) available for artenimol and sirolimus
| Article | Year |
|---|---|
Tackling Fungal Resistance by Biofilm Inhibitors.
Topics: Animals; Antifungal Agents; Biofilms; Drug Discovery; Drug Resistance, Fungal; Fungi; Humans; Models, Molecular; Mycoses; Small Molecule Libraries | 2017 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
1 other study(ies) available for artenimol and sirolimus
| Article | Year |
|---|---|
Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells.
Topics: Apoptosis; Artemisinins; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammasomes; NF-kappa B; Signal Transduction; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2021 |